Tag: guidance

In this 2025 release, Ageless Shoulders expands its digital shoulder mobility system using traditional Indian club exercises to support joint flexibility, address frozen shoulder limitations, and meet rising search demand for non-surgical, at-home movement programs.

Rising search trends for “fireproof document safe,” “estate planning organizer,” and “emergency binder kit” spotlight ICE Box System as a non-digital solution for families protecting vital records and valuables at home.

In this 2025 product availability update, BRĒZ shares how its legal microdosed THC drinks are redefining the fast-growing functional beverage space—offering adults new access to non-alcoholic, hemp-derived cannabis tonics aligned with the search for the best THC drink alternatives.

DRML Miner introduces automated XRP rewards with AI-optimized contract options

Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.

Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.

NativePath’s Clean-Label Creatine Powder Combines L-Leucine, L-Carnitine, and Creatine Monohydrate for Daily Muscle and Energy Support Without Resistance Training

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together with the Series A-2 Warrants, the “Existing Warrants”) at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.